Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P06889 (
Mol
)
630,302
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A molecular structure is an essential source to identify ligand binding sites in orphan human
cytochrome P450 4A22
(
CYP4A22
) that belongs to family 4, which is known to be involved in the regulation of blood pressure. Thus, a homology model has been constructed for
CYP4A22
and refined by molecular dynamics simulation (MDS). Subsequently, molecular docking was performed with possible substrates, arachidonic acid (essential fatty acid, AA) and erythromycin (therapeutic drug, ERY). These complexes were also subjected to MDS, which helped in predicting the energetically favorable binding sites for these ligands. Putative substrate recognition sites (SRSs) of this protein provide highly hydrophobic binding pockets for the target ligands. A few key ligand binding residues identified in this study indicates that they could also play a major role in ligand-channeling (F122, L132 and C230). Furthermore, it appears that they might serve critical support for the catalytic reaction center (E321, F450, P449 and R455). Structural analysis of channels proposed that the conformational changes might have originated from the active site upon ligand binding and transferred to the rest of the protein via SRSs, which could thereby regulate the channels in
CYP4A22
. Most of our prediction results are supported by other research groups. In summary, the first molecular modeling study of
CYP4A22
yields structural knowledge, which would be helpful to design structure-based-drugs and functional experiments for the target protein.
J
Mol
Graph Model 2010 Feb 26
PMID:Molecular modeling study on orphan human protein CYP4A22 for identification of potential ligand binding site. 2007 72